Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Captain James T. Kirk who wrote (454)	4/11/1999 2:21:00 AM
From: Basildon Bond	Respond to of 518

Captain: Try www.ragingbull.com. You'll have to register (free) and then look for the CELN thread. The following is a sample of the quality posting going on over there: CELN Info: I found this info at www.otcfn.com/celn. There is much more there but I thought that this info pertained to alot of recent questions. You can also find this URL at the bottom of Celsion's website. Hope it is helpful. BPH: Once phase one clinical studies are completed at Montefiore Medical Center, multiple-site phase two studies (expected to be finished in 1999) will be conducted to collect the efficacy data necessary to obtain an FDA Premarket Approval (PMA) for commercialization. Breast Cancer: Preclinicals at Hammersmith confirmed the system's safety and effectiveness. Studies at MGH showed it could ablate deep tumors without burning superficial tissues (additional preclinicals are underway to expand the system's indications of use). Clinicals are planned at Hammersmith, MGH, and JFK Medical Center. Prostate Cancer: Preclinicals are being developed at Celsion using a prototype which the Company plans to ship to the University of California at San Francisco for testing in animals to establish the system's safety and efficacy. Deep-seated Cancer: Celsion is developing this prototype for clinical trials to begin at Duke and Northwestern Universities, the latter of which is conducting research on the APA technology under a licensing agreement with MIT. Drug Delivery: Duke and Celsion are developing heat-activated systems to selectively deliver toxic drugs, genetic modifiers, and anti-angiogenesis compounds. Preclinicals showed the entire encapsulated drug content is released within 3 minutes and with 50 times the amount of drug deposited by conventional non-thermosensitive liposomes. FDA Approvals. Celsion received FDA approval to begin clinical trials of its BPH system and has an FDA Premarket Approval for its breast cancer system. Clinicals. BPH clinicals are underway and breast tumor ablation clinicals are scheduled to commence by the end of the year. Additional Technologies. Celsion is applying its technology to develop targeted drug and gene delivery systems for cancer treatment. Strategic Alliances. The Company's superior technologies have attracted some of the world's leading hospitals and most prestigious research institutes where clinicals and further development of CELN's systems continues. Commercialization. BPH system is expected to be launched in late 1999 with $30 million in target revenues by 2001. Breast cancer system is slated for introduction in 2001 with target revenues of $30 million by 2002. See you over there! Regards Basildon Bond